The COVID‐19 pandemic caused by SARS‐Cov‐2 demands rapid, safe and effective therapeutic options. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H 2 S) has emerged as modulator of several biological functions and its deficiency has been associated with different disorders. Therefore, many H 2 S‐releasing agents have been developed as potential therapeutic tools for diseases related with impaired H 2 S production and/or activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H 2 S in modulating the inflammatory response and pro‐inflammatory cytokine cascade is well recognized, and the usefulness of some H 2 S‐donors for the treatment of acute lung inflammation has been reported. Recent data is elucidating several mechanisms of action, which may account for antiviral effects of H 2 S. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H 2 S levels and severity of COVID‐19. Therefore, repurposing of H 2 S‐releasing drugs may be a potential therapeutic opportunity for treatment of COVID‐19. Linked Articles This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc
【저자키워드】 Drug repurposing, SARS‐CoV‐2, Hydrogen sulfide, COVID‐1, H2S‐donor,